CALP2

• UNSPSC Description:

  CALP2 is a calmodulin (CaM) antagonist ( (Kd of 7.9 µM)) with high affinity for binding to the CaM EF-hand/Ca2+-binding site. CALP2 inhibits CaM-dependent phosphodiesterase activity and increases intracellular Ca2+ concentrations. CALP2 potently inhibits of adhesion and degranulation. CALP2 is also a strong activator of alveolar macrophages[1][2][3][4].

• Target Antigen:

  Calmodulin

• Type:

  Peptides

• Related Pathways:

  Membrane Transporter/Ion Channel

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/calp2.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N[C@@H](CCCCN)C(N[C@@H](CC1=CC=CC=C1)C(NCC(N[C@@H](C(C)C)C(NCC(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(N[C@@H](CCSC)C(N[C@@H](C(C)C)C(N[C@@H](CC3=CC=CC=C3)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](C(C)C)N

• Molecular Weight:

  1357.70

• References & Citations:

  [1]R Houtman, et al. Attenuation of very late antigen-5-mediated adhesion of bone marrow-derived mast cells to fibronectin by peptides with inverted hydropathy to EF-hands. J Immunol. 2001 Jan 15;166(2):861-7.|[2]R Ten Broeke, et al. Calcium sensors as new therapeutic targets for airway hyperresponsiveness and asthma. FASEB J. 2001 Aug;15(10):1831-3.|[3]Robert Ten Broeke, et al. Specific modulation of calmodulin activity induces a dramatic production of superoxide by alveolar macrophages. Lab Invest. 2004 Jan;84(1):29-40.|[4]M Villain, et al. De novo design of peptides targeted to the EF hands of calmodulin. J Biol Chem. 2000 Jan 28;275(4):2676-85.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  261969-04-4